APA (7th ed.) Citation

C, Z., P, A., P, N., S, P., S, R., RK, N., . . . SK, B. (2022). Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Cancer letters, 551, 215922. https://doi.org/10.1016/j.canlet.2022.215922

Chicago Style (17th ed.) Citation

C, Zhang, et al. "Small Molecule Inhibitor Against Onco-mucins Disrupts Src/FosL1 Axis to Enhance Gemcitabine Efficacy in Pancreatic Ductal Adenocarcinoma." Cancer Letters 551 (2022): 215922. https://doi.org/10.1016/j.canlet.2022.215922.

MLA (9th ed.) Citation

C, Zhang, et al. "Small Molecule Inhibitor Against Onco-mucins Disrupts Src/FosL1 Axis to Enhance Gemcitabine Efficacy in Pancreatic Ductal Adenocarcinoma." Cancer Letters, vol. 551, 2022, p. 215922, https://doi.org/10.1016/j.canlet.2022.215922.